North Dallas Bank & Trust Co. Buys Shares of 14,888 Johnson & Johnson $JNJ

North Dallas Bank & Trust Co. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 14,888 shares of the company’s stock, valued at approximately $2,274,000. Johnson & Johnson comprises approximately 1.7% of North Dallas Bank & Trust Co.’s portfolio, making the stock its 16th largest holding.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank raised its holdings in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares in the last quarter. Cookson Peirce & Co. Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter worth about $208,000. EverSource Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 10.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 19,646 shares of the company’s stock worth $3,258,000 after acquiring an additional 1,863 shares in the last quarter. Finally, Forvis Mazars Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 37.6% in the 1st quarter. Forvis Mazars Wealth Advisors LLC now owns 58,656 shares of the company’s stock valued at $9,728,000 after acquiring an additional 16,019 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Guggenheim upped their target price on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday. Raymond James Financial boosted their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Wells Fargo & Company raised their price target on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Friday. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $207.55.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $211.65 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm’s 50-day moving average is $196.09 and its 200-day moving average is $177.25. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $212.27. The company has a market cap of $509.93 billion, a price-to-earnings ratio of 20.43, a PEG ratio of 2.36 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.